Experienced Senior Team Overview slide image

Experienced Senior Team Overview

AC (continued) Terry Walters joined Twin Brook in 2019 as Chief Accounting Officer in the firm's middle market direct lending loan business. Prior to joining the firm, Terry spent eight years in various roles with Victory Park Capital Advisors and Vitalogy Capital Partners. Prior to that, Terry worked at Citadel Group's fund administrator, Omnium, as well as Ernst & Young LLP. Terry holds a B.A. in accountancy and finance from Augustana College and a M.Acc. degree from the University of lowa. He is a Certified Public Accountant (inactive). Middle Market Direct Lending Team Tim Wentink joined Angelo Gordon in 2019 as a Managing Director in the firm's middle market direct lending loan business. Tim focuses on originating, structuring, underwriting, and negotiating healthcare transactions. Prior to joining the firm, Tim spent 11 years with Madison Capital Funding LLC, as part of the company's Healthcare Leveraged Finance group. Previously, Tim held various positions within Merrill Lynch Capital Healthcare Finance's leveraged lending group, as well as JPMorgan Chase's commercial lending group. Tim received a B.S. degree in Finance from the University of Illinois at Urbana-Champaign and holds the Chartered Financial Analyst (CFA) designation. Michael Gordon is the Chief Executive Officer and Co-Chief Investment Officer of Angelo Gordon, and chairs the Firm's Management Committee. As CEO, Michael is responsible for the overall management of the firm and works with his co-CIOs to manage the diverse investment ideas within each discipline to provide an appropriate balance of risk and reward. He oversees the Research Department and is responsible for the quality and depth of research that is the hallmark of Angelo Gordon. Michael began his career as a research analyst for L.F. Rothschild in 1970, specializing in the oil and oil service industries. Michael served as Director of Research of L.F. Rothschild's Arbitrage Department and became a Managing Director of the firm. Michael is on the Board of Directors of the Damon Runyon Cancer Research Foundation and Conquer Cancer Foundation. He is a Trustee of Colby College and the Boston Symphony Orchestra. Michael has a B.A. degree from Colby College and a J.D. degree from Boston University Law School. Josh Baumgarten is co-Chief Investment Officer of Angelo Gordon and a member of the Management Committee. He leads the Firm's Credit business and is co-portfolio manager for AG Super Fund and multi-strategy portfolios. Prior to joining Angelo Gordon in 2016, Josh was a Senior Managing Director at Blackstone and focused on Blackstone Alternative Asset Management, the firm's hedge fund solutions business. At BAAM, which he joined in 2007, Josh oversaw credit investing and worked closely with some of the most well-regarded credit investors around the globe. He played a key role in Blackstone's global co-investment business. Prior to Blackstone, Josh was a Portfolio Manager and trader at Blackrock, which he joined in 2000. His principal focus was on Blackrock's high-yield portfolios. Josh started his career at Jefferies in investment banking and also spent time early in his career in venture capital investing. Josh is a member of the Children's Board at Columbia (Columbia University Medical Center). He has a B.S. degree in Economics with concentrations in Finance and Accounting from The Wharton School at the University of Pennsylvania. Maureen D'Alleva joined Angelo Gordon in 2003 and is head of the firm's performing credit business. Maureen is a Managing Director and a member of the firm's executive committee. She is also the portfolio manager of the firm's dedicated performing credit portfolios, as well as its Northwoods Capital CLOS. Prior to joining the firm, she spent 15 years with Morgan Stanley as a Vice President in its Global High Yield group where she focused on investment analysis and underwriting of both bank loans and bonds. Maureen holds a B.A. degree from Baruch College. AG Page 115 Proprietary and Confidential Trade Secret 36
View entire presentation